Analysts expect BridgeBio Oncology Therapeutics, Inc. to report revenue of 0.00 for Q2 26, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 26, came in at 0.00.
| Metric | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
| Low Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||||||||
| Consensus Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analysts expect BridgeBio Oncology Therapeutics, Inc. to report earnings per share of -0.57 for Q2 26, against a range of -0.60 to -0.54. The most recent reported quarter, Q1 26, came in at -0.53, a 12.8% miss against the -0.47 consensus.
| Metric | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 | Q1 29 | Q2 29 | Q3 29 | Q4 29 | Q1 30 | Q2 30 | Q3 30 | Q4 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -52.15 | -50.34 | -1.03 | -0.49 | -0.53 | - | - | - | - | - | - | - | - | |||||||||||
| High Estimate | - | -42.29 | -0.35 | -0.55 | -0.44 | -0.54 | -0.59 | -0.49 | -0.48 | 10.16 | 14.68 | 5.13 | -9.15 | |||||||||||
| Low Estimate | - | -48.25 | -0.39 | -0.63 | -0.50 | -0.60 | -0.65 | -0.59 | -0.54 | 9.50 | 13.80 | 4.77 | -9.93 | |||||||||||
| Consensus Estimate | - | -45.27 | -0.37 | -0.59 | -0.47 | -0.57 | -0.62 | -0.54 | -0.51 | 9.83 | 14.24 | 4.95 | -9.54 |